Jennifer Matthews: Multiple myeloma -- two words no one wants to hear. When Jim Bond was handed the diagnosis 10 years ago, he fought back.
Jim Bond: Everybody has their own way of dealing with cancer. My way is to start looking for what I can do next and how I can try to make it better.
Jennifer Matthews: Three transplants and many treatments later, Bond finally hit the end of the road this past April.
Jim Bond: I was not able to eat anything to speak of. I was running high fevers.
Jennifer Matthews: But giving up isn't Bond's style. Searching for another shot at remission, he found medical oncologist Paul Richardson, and the drug, mln-341. The drug targets myeloma cells and disrupts their growth.
Dr. Paul Richardson: If you disrupt that process in the myeloma cell, it triggers what we call programmed cell death so that the myeloma cell dies.
Jennifer Matthews: The first patients to receive the drug had been heavily treated with standard therapy. Despite this, their cancer returned and progressed. Mln-341 was a last hope.
Dr. Paul Richardson: Three quarters either stabilized or got better. And for such a poor prognosis group, that obviously was a very compelling result.
Jennifer Matthews: Jim relocated to Boston for the nine-month treatment.
Jim Bond: I'm absolutely thrilled to say that 99 percent of my cancer level is gone. It's in remission.
Jennifer Matthews: The drug is working, but he will be ready if his cancer returns.
Jim Bond: The attitude part, I think, is where the game is won or lost.
Jennifer Matthews: For Jim enjoys these sites and the time with his wife Cathleen. This is Jennifer Matthews reporting.
Jennifer Matthews: Multiple myeloma -- two words no one wants to hear. When Jim Bond was handed the diagnosis 10 years ago, he fought back.
Jim Bond: Everybody has their own way of dealing with cancer. My way is to start looking for what I can do next and how I can try to make it better.
Jennifer Matthews: Three transplants and many treatments later, Bond finally hit the end of the road this past April.
Jim Bond: I was not able to eat anything to speak of. I was running high fevers.
Jennifer Matthews: But giving up isn't Bond's style. Searching for another shot at remission, he found medical oncologist Paul Richardson, and the drug, mln-341. The drug targets myeloma cells and disrupts their growth.
Dr. Paul Richardson: If you disrupt that process in the myeloma cell, it triggers what we call programmed cell death so that the myeloma cell dies.
Jennifer Matthews: The first patients to receive the drug had been heavily treated with standard therapy. Despite this, their cancer returned and progressed. Mln-341 was a last hope.
Dr. Paul Richardson: Three quarters either stabilized or got better. And for such a poor prognosis group, that obviously was a very compelling result.
Jennifer Matthews: Jim relocated to Boston for the nine-month treatment.
Jim Bond: I'm absolutely thrilled to say that 99 percent of my cancer level is gone. It's in remission.
Jennifer Matthews: The drug is working, but he will be ready if his cancer returns.
Jim Bond: The attitude part, I think, is where the game is won or lost.
Jennifer Matthews: For Jim enjoys these sites and the time with his wife Cathleen. This is Jennifer Matthews reporting.
Transcription by:
Scribe4you Transcription Services